Key result
ICH S7B best-practice patch clamp assays improve alignment of ion channel IC50s with clinical ECGs.
Why the study?
Several studies under the CiPA initiative showed misalignment between nonclinical ion channel data and clinical ECG changes or Torsade de Pointes risk, alongside unintegrated data for hERG-active metabolites. Addressing these inconsistencies and metabolite data gaps was needed to increase confidence in using nonclinical data for regulatory decision-making.
Does reassessing cardiac ion channel block using protocols consistent with ICH S7B Q&A 2.1 best practices and accounting for hERG-active metabolites improve the alignment between nonclinical in vitro data and clinical ECG changes and Torsade de Pointes risk?
Does reassessing cardiac ion channel block using protocols consistent with ICH S7B Q&A 2.1 best practices and accounting for hERG-active metabolites improve the alignment between nonclinical in vitro data and clinical ECG changes and Torsade de Pointes risk?
Conducting in vitro patch clamp cardiac ion channel assays in accordance with ICH S7B Q&A 2.1 best practices and integrating data for active metabolites reconciles previous discrepancies between nonclinical pharmacology profiles and clinical ECG changes and proarrhythmia risk.
Answers are grounded in this paper and cite their sources.
Refined protocols may improve proarrhythmia risk prediction; extends CiPA but leaves clinical translation open pending validation.
The Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative proposes integrating multi‐cardiac ion channel pharmacology to improve the prediction of drug‐induced Torsade de Pointes (TdP) risk. However, several studies under CiPA have demonstrated misalignment between nonclinical and clinical data. One study showed ECG changes induced by chloroquine, lopinavir, and ritonavir suggestive of Ca V 1.2 and Na V 1.5 channel block. However, ion channel data used to design the clinical study showed no such interactions. Another study reported TdP cases in patients treated with vanoxerine, a drug with literature data demonstrating similar block potencies for hERG and Ca V 1.2 channels suggesting lower TdP risk than selective hERG blockers. Finally, astemizole, risperidone, and clarithromycin—“intermediate TdP risk” CiPA drugs—were reported to have hERG‐active metabolites, yet hERG data for metabolites were not integrated when developing in silico human myocyte models for risk prediction. To increase the confidence of using nonclinical data in regulatory decision‐making, the sources of these inconsistent nonclinical‐clinical findings and data gap for metabolites need to be addressed. Here the effects of chloroquine, lopinavir, ritonavir, and vanoxerine on hERG, Ca V 1.2, and/or Na V 1.5 channels were studied using protocols consistent with ICH S7B Q&A 2.1 best practices. hERG block potencies for astemizole, risperidone, clarithromycin plus their major metabolites were also determined. The results showed improved alignment between ion channel block profiles and drug‐induced ECG changes and proarrhythmia, underscoring the importance of using physiologically relevant experimental protocols, accounting for ion channel‐active metabolites, and continuing to build the knowledge base of arrhythmogenesis mechanisms. Data may be found at: https://osf.io/7rfua/ .
No takes yet. Share an insight, caveat, or question.
Baron et al. (2025) studied Drug-induced Torsade de Pointes (TdP) and ECG interval prolongation risk. Physiologically relevant patch clamp protocols (ICH S7B Q&A 2.1 best practices) evaluating chloroquine, lopinavir, ritonavir, vanoxerine, verapamil, ranolazine, and hERG-active metabolites of astemizole, risperidone, and clarithromycin vs. Vehicle control solutions and prior literature patch clamp protocols was evaluated on Half-maximal inhibitory concentration (IC50) for cardiac ion channel currents (IhERG, ICa, INaP, INaL) and hERG safety margins. Patch clamp assays following ICH S7B Q&A 2.1 best practices yielded ion channel IC50 values and metabolite safety margins that better aligned with clinical ECGs.
Synapse has enriched 10 related papers. Consider them for comparative context: